Skip to main content
Top
Published in: Molecular Neurodegeneration 1/2013

Open Access 01-12-2013 | Research article

rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration

Authors: Marusela Oliveras-Salvá, Anke Van der Perren, Nicolas Casadei, Stijn Stroobants, Silke Nuber, Rudi D’Hooge, Chris Van den Haute, Veerle Baekelandt

Published in: Molecular Neurodegeneration | Issue 1/2013

Login to get access

Abstract

Background

Alpha-synuclein is a key protein implicated in the pathogenesis of Parkinson's disease (PD). It is the main component of the Lewy bodies, a cardinal neuropathological feature in the disease. In addition, whole locus multiplications and point mutations in the gene coding for alpha-synuclein lead to autosomal dominant monogenic PD. Over the past decade, research on PD has impelled the development of new animal models based on alpha-synuclein. In this context, transgenic mouse lines have failed to reproduce several hallmarks of PD, especially the strong and progressive dopaminergic neurodegeneration over time that occurs in the patients. In contrast, viral vector-based models in rats and non-human primates display prominent, although highly variable, nigral dopaminergic neuron loss. However, the few studies available on viral vector-mediated overexpression of alpha-synuclein in mice report a weak neurodegenerative process and no clear Lewy body-like pathology. To address this issue, we performed a comprehensive comparative study of alpha-synuclein overexpression by means of recombinant adeno-associated viral vectors serotype 2/7 (rAAV2/7) at different doses in adult mouse substantia nigra.

Results

We noted a significant and dose-dependent alpha-synucleinopathy over time upon nigral viral vector-mediated alpha-synuclein overexpression. We obtained a strong, progressive and dose-dependent loss of dopaminergic neurons in the substantia nigra, reaching a maximum of 82% after 8 weeks. This effect correlated with a reduction in tyrosine hydroxylase immunoreactivity in the striatum. Moreover, behavioural analysis revealed significant motor impairments from 12 weeks after injection on. In addition, we detected the presence of alpha-synuclein-positive aggregates in the remaining surviving neurons. When comparing wild-type to mutant A53T alpha-synuclein at the same vector dose, both induced a similar degree of cell death. These data were supported by a biochemical analysis that showed a net increase in soluble and insoluble alpha-synuclein expression over time to the same extent for both alpha-synuclein variants.

Conclusions

In conclusion, our in vivo data provide evidence that strong and significant alpha-synuclein-induced neuropathology and progressive dopaminergic neurodegeneration can be achieved in mouse brain by means of rAAV2/7.
Appendix
Available only for authorised users
Literature
1.
go back to reference Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: Alpha-synuclein in Lewy bodies. Nature. 1997, 388: 839-840. 10.1038/42166.CrossRefPubMed Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: Alpha-synuclein in Lewy bodies. Nature. 1997, 388: 839-840. 10.1038/42166.CrossRefPubMed
2.
go back to reference Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, et al: Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004, 364: 1167-1169. 10.1016/S0140-6736(04)17103-1.CrossRefPubMed Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, et al: Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004, 364: 1167-1169. 10.1016/S0140-6736(04)17103-1.CrossRefPubMed
3.
go back to reference Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O: Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998, 18: 106-108. 10.1038/ng0298-106.CrossRefPubMed Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O: Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998, 18: 106-108. 10.1038/ng0298-106.CrossRefPubMed
4.
go back to reference Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al: Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997, 276: 2045-2047. 10.1126/science.276.5321.2045.CrossRefPubMed Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al: Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997, 276: 2045-2047. 10.1126/science.276.5321.2045.CrossRefPubMed
5.
go back to reference Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, et al: alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003, 302: 841-10.1126/science.1090278.CrossRefPubMed Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, et al: alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003, 302: 841-10.1126/science.1090278.CrossRefPubMed
6.
go back to reference Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, et al: The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004, 55: 164-173. 10.1002/ana.10795.CrossRefPubMed Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, et al: The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004, 55: 164-173. 10.1002/ana.10795.CrossRefPubMed
7.
go back to reference Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P, Proukakis C, Quinn N, Lees AJ, Hardy J, Revesz T, Houlden H, Holton JL: Alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy?. Acta Neuropathol. 2013, 125 (5): 753-769. 10.1007/s00401-013-1096-7.PubMedCentralCrossRefPubMed Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P, Proukakis C, Quinn N, Lees AJ, Hardy J, Revesz T, Houlden H, Holton JL: Alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson’s disease and multiple system atrophy?. Acta Neuropathol. 2013, 125 (5): 753-769. 10.1007/s00401-013-1096-7.PubMedCentralCrossRefPubMed
8.
go back to reference Proukakis C, Dudzik CG, Brier T, Mackay DS, Cooper JM, Millhauser GL, Houlden H, Schapira AH: A novel alpha-synuclein missense mutation in Parkinson disease. Neurology. 2013, 80: 1062-1064. 10.1212/WNL.0b013e31828727ba.PubMedCentralCrossRefPubMed Proukakis C, Dudzik CG, Brier T, Mackay DS, Cooper JM, Millhauser GL, Houlden H, Schapira AH: A novel alpha-synuclein missense mutation in Parkinson disease. Neurology. 2013, 80: 1062-1064. 10.1212/WNL.0b013e31828727ba.PubMedCentralCrossRefPubMed
9.
go back to reference Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, Brice A: Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet. 2004, 364: 1169-1171. 10.1016/S0140-6736(04)17104-3.CrossRefPubMed Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, Brice A: Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet. 2004, 364: 1169-1171. 10.1016/S0140-6736(04)17104-3.CrossRefPubMed
10.
go back to reference Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, et al: Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 2009, 41: 1303-1307. 10.1038/ng.485.CrossRefPubMed Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, et al: Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 2009, 41: 1303-1307. 10.1038/ng.485.CrossRefPubMed
11.
go back to reference Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, et al: Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009, 41: 1308-1312. 10.1038/ng.487.PubMedCentralCrossRefPubMed Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, et al: Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009, 41: 1308-1312. 10.1038/ng.487.PubMedCentralCrossRefPubMed
12.
go back to reference Chesselet MF, Richter F: Modelling of Parkinson's disease in mice. Lancet Neurol. 2011, 10: 1108-1118. 10.1016/S1474-4422(11)70227-7.CrossRefPubMed Chesselet MF, Richter F: Modelling of Parkinson's disease in mice. Lancet Neurol. 2011, 10: 1108-1118. 10.1016/S1474-4422(11)70227-7.CrossRefPubMed
13.
go back to reference Kahle PJ: alpha-Synucleinopathy models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115: 87-95.CrossRefPubMed Kahle PJ: alpha-Synucleinopathy models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115: 87-95.CrossRefPubMed
14.
go back to reference Low K, Aebischer P: Use of viral vectors to create animal models for Parkinson's disease. Neurobiol Dis. 2012, 48: 189-201. 10.1016/j.nbd.2011.12.038.CrossRefPubMed Low K, Aebischer P: Use of viral vectors to create animal models for Parkinson's disease. Neurobiol Dis. 2012, 48: 189-201. 10.1016/j.nbd.2011.12.038.CrossRefPubMed
15.
go back to reference Lauwers E, Beque D, Van Laere K, Nuyts J, Bormans G, Mortelmans L, Casteels C, Vercammen L, Bockstael O, Nuttin B, et al: Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. Neurobiol Aging. 2007, 28: 248-257. 10.1016/j.neurobiolaging.2005.12.005.CrossRefPubMed Lauwers E, Beque D, Van Laere K, Nuyts J, Bormans G, Mortelmans L, Casteels C, Vercammen L, Bockstael O, Nuttin B, et al: Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. Neurobiol Aging. 2007, 28: 248-257. 10.1016/j.neurobiolaging.2005.12.005.CrossRefPubMed
16.
go back to reference Lauwers E, Debyser Z, Van Dorpe J, De Strooper B, Nuttin B, Baekelandt V: Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol. 2003, 13: 364-372.CrossRefPubMed Lauwers E, Debyser Z, Van Dorpe J, De Strooper B, Nuttin B, Baekelandt V: Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol. 2003, 13: 364-372.CrossRefPubMed
17.
go back to reference Gerard M, Deleersnijder A, Daniels V, Schreurs S, Munck S, Reumers V, Pottel H, Engelborghs Y, Van den Haute C, Taymans JM, et al: Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology. J Neurosci. 2010, 30: 2454-2463. 10.1523/JNEUROSCI.5983-09.2010.CrossRefPubMed Gerard M, Deleersnijder A, Daniels V, Schreurs S, Munck S, Reumers V, Pottel H, Engelborghs Y, Van den Haute C, Taymans JM, et al: Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology. J Neurosci. 2010, 30: 2454-2463. 10.1523/JNEUROSCI.5983-09.2010.CrossRefPubMed
18.
go back to reference Taymans JM, Vandenberghe LH, Haute CV, Thiry I, Deroose CM, Mortelmans L, Wilson JM, Debyser Z, Baekelandt V: Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther. 2007, 18: 195-206. 10.1089/hum.2006.178.CrossRefPubMed Taymans JM, Vandenberghe LH, Haute CV, Thiry I, Deroose CM, Mortelmans L, Wilson JM, Debyser Z, Baekelandt V: Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther. 2007, 18: 195-206. 10.1089/hum.2006.178.CrossRefPubMed
19.
go back to reference Van der Perren A, Toelen J, Carlon M, Van den Haute C, Coun F, Heeman B, Reumers V, Vandenberghe LH, Wilson JM, Debyser Z, Baekelandt V: Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9. Gene Ther. 2011, 18: 517-527. 10.1038/gt.2010.179.CrossRefPubMed Van der Perren A, Toelen J, Carlon M, Van den Haute C, Coun F, Heeman B, Reumers V, Vandenberghe LH, Wilson JM, Debyser Z, Baekelandt V: Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9. Gene Ther. 2011, 18: 517-527. 10.1038/gt.2010.179.CrossRefPubMed
20.
go back to reference Reimsnider S, Manfredsson FP, Muzyczka N, Mandel RJ: Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol Ther. 2007, 15: 1504-1511. 10.1038/sj.mt.6300227.CrossRefPubMed Reimsnider S, Manfredsson FP, Muzyczka N, Mandel RJ: Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol Ther. 2007, 15: 1504-1511. 10.1038/sj.mt.6300227.CrossRefPubMed
21.
go back to reference Markakis EA, Vives KP, Bober J, Leichtle S, Leranth C, Beecham J, Elsworth JD, Roth RH, Samulski RJ, Redmond DE: Comparative transduction efficiency of AAV vector serotypes 1–6 in the substantia nigra and striatum of the primate brain. Mol Ther. 2010, 18: 588-593. 10.1038/mt.2009.286.PubMedCentralCrossRefPubMed Markakis EA, Vives KP, Bober J, Leichtle S, Leranth C, Beecham J, Elsworth JD, Roth RH, Samulski RJ, Redmond DE: Comparative transduction efficiency of AAV vector serotypes 1–6 in the substantia nigra and striatum of the primate brain. Mol Ther. 2010, 18: 588-593. 10.1038/mt.2009.286.PubMedCentralCrossRefPubMed
22.
go back to reference Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier PJ, Mandel RJ, Muzyczka N: Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther. 2004, 10: 302-317. 10.1016/j.ymthe.2004.05.024.CrossRefPubMed Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier PJ, Mandel RJ, Muzyczka N: Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther. 2004, 10: 302-317. 10.1016/j.ymthe.2004.05.024.CrossRefPubMed
23.
go back to reference Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Bjorklund A: Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci. 2002, 22: 2780-2791.PubMed Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Bjorklund A: Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci. 2002, 22: 2780-2791.PubMed
24.
go back to reference Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H: Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem. 2004, 91: 451-461. 10.1111/j.1471-4159.2004.02728.x.CrossRefPubMed Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H: Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem. 2004, 91: 451-461. 10.1111/j.1471-4159.2004.02728.x.CrossRefPubMed
25.
go back to reference Decressac M, Mattsson B, Lundblad M, Weikop P, Bjorklund A: Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis. 2012, 45: 939-953. 10.1016/j.nbd.2011.12.013.CrossRefPubMed Decressac M, Mattsson B, Lundblad M, Weikop P, Bjorklund A: Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol Dis. 2012, 45: 939-953. 10.1016/j.nbd.2011.12.013.CrossRefPubMed
26.
go back to reference McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ: Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol. 2009, 68: 515-524. 10.1097/NEN.0b013e3181a24b53.PubMedCentralCrossRefPubMed McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ: Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol. 2009, 68: 515-524. 10.1097/NEN.0b013e3181a24b53.PubMedCentralCrossRefPubMed
27.
go back to reference Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M: Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One. 2010, 5: e8784-10.1371/journal.pone.0008784.PubMedCentralCrossRefPubMed Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M: Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One. 2010, 5: e8784-10.1371/journal.pone.0008784.PubMedCentralCrossRefPubMed
28.
go back to reference Koprich JB, Johnston TH, Reyes MG, Sun X, Brotchie JM: Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. Mol Neurodegener. 2010, 5: 43-10.1186/1750-1326-5-43.PubMedCentralCrossRefPubMed Koprich JB, Johnston TH, Reyes MG, Sun X, Brotchie JM: Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. Mol Neurodegener. 2010, 5: 43-10.1186/1750-1326-5-43.PubMedCentralCrossRefPubMed
29.
go back to reference Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Bjorklund A: Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A. 2003, 100: 2884-2889. 10.1073/pnas.0536383100.PubMedCentralCrossRefPubMed Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Bjorklund A: Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A. 2003, 100: 2884-2889. 10.1073/pnas.0536383100.PubMedCentralCrossRefPubMed
30.
go back to reference Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T: alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002, 4: 160-164.CrossRefPubMed Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T: alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002, 4: 160-164.CrossRefPubMed
31.
go back to reference Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, et al: Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006, 281: 29739-29752. 10.1074/jbc.M600933200.CrossRefPubMed Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, et al: Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006, 281: 29739-29752. 10.1074/jbc.M600933200.CrossRefPubMed
32.
go back to reference Van der Perren A, Toelen J, Taymans JM, Baekelandt V: Using recombinant adeno-associated viral vectors for gene expression in the brain. Neuromethods. 2012, 65: 47-68.CrossRef Van der Perren A, Toelen J, Taymans JM, Baekelandt V: Using recombinant adeno-associated viral vectors for gene expression in the brain. Neuromethods. 2012, 65: 47-68.CrossRef
33.
go back to reference Cao S, Theodore S, Standaert DG: Fcgamma receptors are required for NF-kappaB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease. Mol Neurodegener. 2010, 5: 42-10.1186/1750-1326-5-42.PubMedCentralCrossRefPubMed Cao S, Theodore S, Standaert DG: Fcgamma receptors are required for NF-kappaB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease. Mol Neurodegener. 2010, 5: 42-10.1186/1750-1326-5-42.PubMedCentralCrossRefPubMed
34.
go back to reference Theodore S, Cao S, McLean PJ, Standaert DG: Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol. 2008, 67: 1149-1158. 10.1097/NEN.0b013e31818e5e99.PubMedCentralCrossRefPubMed Theodore S, Cao S, McLean PJ, Standaert DG: Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol. 2008, 67: 1149-1158. 10.1097/NEN.0b013e31818e5e99.PubMedCentralCrossRefPubMed
35.
go back to reference St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I, Grammatopoulos TN, Standaert DG, Hyman BT, McLean PJ: Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem. 2007, 100: 1449-1457.PubMed St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I, Grammatopoulos TN, Standaert DG, Hyman BT, McLean PJ: Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem. 2007, 100: 1449-1457.PubMed
36.
go back to reference Dong Z, Ferger B, Feldon J, Bueler H: Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. J Neurobiol. 2002, 53: 1-10. 10.1002/neu.10094.CrossRefPubMed Dong Z, Ferger B, Feldon J, Bueler H: Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. J Neurobiol. 2002, 53: 1-10. 10.1002/neu.10094.CrossRefPubMed
37.
go back to reference Yasuda T, Nihira T, Ren YR, Cao XQ, Wada K, Setsuie R, Kabuta T, Hattori N, Mizuno Y, Mochizuki H: Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease. J Neurochem. 2009, 108: 932-944. 10.1111/j.1471-4159.2008.05827.x.CrossRefPubMed Yasuda T, Nihira T, Ren YR, Cao XQ, Wada K, Setsuie R, Kabuta T, Hattori N, Mizuno Y, Mochizuki H: Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease. J Neurochem. 2009, 108: 932-944. 10.1111/j.1471-4159.2008.05827.x.CrossRefPubMed
38.
go back to reference Ulusoy A, Bjorklund T, Buck K, Kirik D: Dysregulated dopamine storage increases the vulnerability to alpha-synuclein in nigral neurons. Neurobiol Dis. 2012, 47: 367-377. 10.1016/j.nbd.2012.05.012.CrossRefPubMed Ulusoy A, Bjorklund T, Buck K, Kirik D: Dysregulated dopamine storage increases the vulnerability to alpha-synuclein in nigral neurons. Neurobiol Dis. 2012, 47: 367-377. 10.1016/j.nbd.2012.05.012.CrossRefPubMed
39.
go back to reference Gao G, Vandenberghe LH, Wilson JM: New recombinant serotypes of AAV vectors. Curr Gene Ther. 2005, 5: 285-297. 10.2174/1566523054065057.CrossRefPubMed Gao G, Vandenberghe LH, Wilson JM: New recombinant serotypes of AAV vectors. Curr Gene Ther. 2005, 5: 285-297. 10.2174/1566523054065057.CrossRefPubMed
40.
go back to reference Paxinos G, Franklin KBJ: The Mouse Brain in Stereotaxic Coordinates. 2001, San Diego: Academic Press Paxinos G, Franklin KBJ: The Mouse Brain in Stereotaxic Coordinates. 2001, San Diego: Academic Press
41.
go back to reference George S, Mok SS, Nurjono M, Ayton S, Finkelstein DI, Masters CL, Li QX, Culvenor JG: alpha-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced alpha-synuclein and PINK1 levels after rotenone treatment. J Mol Neurosci. 2010, 42: 243-254. 10.1007/s12031-010-9378-1.CrossRefPubMed George S, Mok SS, Nurjono M, Ayton S, Finkelstein DI, Masters CL, Li QX, Culvenor JG: alpha-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced alpha-synuclein and PINK1 levels after rotenone treatment. J Mol Neurosci. 2010, 42: 243-254. 10.1007/s12031-010-9378-1.CrossRefPubMed
42.
go back to reference Baekelandt V, Claeys A, Eggermont K, Lauwers E, De Strooper B, Nuttin B, Debyser Z: Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. Hum Gene Ther. 2002, 13: 841-853. 10.1089/10430340252899019.CrossRefPubMed Baekelandt V, Claeys A, Eggermont K, Lauwers E, De Strooper B, Nuttin B, Debyser Z: Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. Hum Gene Ther. 2002, 13: 841-853. 10.1089/10430340252899019.CrossRefPubMed
43.
go back to reference Vercammen L, Van der Perren A, Vaudano E, Gijsbers R, Debyser Z, Van den Haute C, Baekelandt V: Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Mol Ther. 2006, 14: 716-723. 10.1016/j.ymthe.2006.06.009.CrossRefPubMed Vercammen L, Van der Perren A, Vaudano E, Gijsbers R, Debyser Z, Van den Haute C, Baekelandt V: Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Mol Ther. 2006, 14: 716-723. 10.1016/j.ymthe.2006.06.009.CrossRefPubMed
44.
go back to reference Schmitz C, Hof PR: Design-based stereology in neuroscience. Neuroscience. 2005, 130: 813-831. 10.1016/j.neuroscience.2004.08.050.CrossRefPubMed Schmitz C, Hof PR: Design-based stereology in neuroscience. Neuroscience. 2005, 130: 813-831. 10.1016/j.neuroscience.2004.08.050.CrossRefPubMed
45.
go back to reference Gundersen HJ, Jensen EB: The efficiency of systematic sampling in stereology and its prediction. J Microsc. 1987, 147: 229-263. 10.1111/j.1365-2818.1987.tb02837.x.CrossRefPubMed Gundersen HJ, Jensen EB: The efficiency of systematic sampling in stereology and its prediction. J Microsc. 1987, 147: 229-263. 10.1111/j.1365-2818.1987.tb02837.x.CrossRefPubMed
46.
go back to reference Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG: Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem. 2003, 278: 44405-44411. 10.1074/jbc.M308041200.CrossRefPubMed Tofaris GK, Razzaq A, Ghetti B, Lilley KS, Spillantini MG: Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem. 2003, 278: 44405-44411. 10.1074/jbc.M308041200.CrossRefPubMed
47.
go back to reference Nuber S, Franck T, Wolburg H, Schumann U, Casadei N, Fischer K, Calaminus C, Pichler BJ, Chanarat S, Teismann P, et al: Transgenic overexpression of the alpha-synuclein interacting protein synphilin-1 leads to behavioral and neuropathological alterations in mice. Neurogenetics. 2010, 11: 107-120. 10.1007/s10048-009-0212-2.CrossRefPubMed Nuber S, Franck T, Wolburg H, Schumann U, Casadei N, Fischer K, Calaminus C, Pichler BJ, Chanarat S, Teismann P, et al: Transgenic overexpression of the alpha-synuclein interacting protein synphilin-1 leads to behavioral and neuropathological alterations in mice. Neurogenetics. 2010, 11: 107-120. 10.1007/s10048-009-0212-2.CrossRefPubMed
48.
go back to reference Paleologou KE, Kragh CL, Mann DM, Salem SA, Al-Shami R, Allsop D, Hassan AH, Jensen PH, El-Agnaf OM: Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain. 2009, 132: 1093-1101.CrossRefPubMed Paleologou KE, Kragh CL, Mann DM, Salem SA, Al-Shami R, Allsop D, Hassan AH, Jensen PH, El-Agnaf OM: Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain. 2009, 132: 1093-1101.CrossRefPubMed
49.
go back to reference Lue LF, Walker DG, Adler CH, Shill H, Tran H, Akiyama H, Sue LI, Caviness J, Sabbagh MN, Beach TG: Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol. 2012, 22: 745-756. 10.1111/j.1750-3639.2012.00585.x.PubMedCentralCrossRefPubMed Lue LF, Walker DG, Adler CH, Shill H, Tran H, Akiyama H, Sue LI, Caviness J, Sabbagh MN, Beach TG: Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol. 2012, 22: 745-756. 10.1111/j.1750-3639.2012.00585.x.PubMedCentralCrossRefPubMed
50.
go back to reference Ulusoy A, Decressac M, Kirik D, Bjorklund A: Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease. Prog Brain Res. 2010, 184: 89-111.CrossRefPubMed Ulusoy A, Decressac M, Kirik D, Bjorklund A: Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease. Prog Brain Res. 2010, 184: 89-111.CrossRefPubMed
51.
go back to reference Burre J, Sharma M, Sudhof TC: Systematic mutagenesis of alpha-synuclein reveals distinct sequence requirements for physiological and pathological activities. J Neurosci. 2012, 32: 15227-15242. 10.1523/JNEUROSCI.3545-12.2012.PubMedCentralCrossRefPubMed Burre J, Sharma M, Sudhof TC: Systematic mutagenesis of alpha-synuclein reveals distinct sequence requirements for physiological and pathological activities. J Neurosci. 2012, 32: 15227-15242. 10.1523/JNEUROSCI.3545-12.2012.PubMedCentralCrossRefPubMed
52.
go back to reference Azeredo da Silveira S, Schneider BL, Cifuentes-Diaz C, Sage D, Abbas-Terki T, Iwatsubo T, Unser M, Aebischer P: Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum Mol Genet. 2009, 18: 872-887.PubMed Azeredo da Silveira S, Schneider BL, Cifuentes-Diaz C, Sage D, Abbas-Terki T, Iwatsubo T, Unser M, Aebischer P: Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum Mol Genet. 2009, 18: 872-887.PubMed
53.
go back to reference Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM: Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. PLoS One. 2011, 6: e17698-10.1371/journal.pone.0017698.PubMedCentralCrossRefPubMed Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM: Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. PLoS One. 2011, 6: e17698-10.1371/journal.pone.0017698.PubMedCentralCrossRefPubMed
54.
go back to reference Lock M, Alvira M, Vandenberghe LH, Samanta A, Toelen J, Debyser Z, Wilson JM: Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther. 2010, 21: 1259-1271. 10.1089/hum.2010.055.PubMedCentralCrossRefPubMed Lock M, Alvira M, Vandenberghe LH, Samanta A, Toelen J, Debyser Z, Wilson JM: Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther. 2010, 21: 1259-1271. 10.1089/hum.2010.055.PubMedCentralCrossRefPubMed
55.
go back to reference Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, Kirik D: Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain. 2007, 130: 799-815. 10.1093/brain/awl382.CrossRefPubMed Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, Kirik D: Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain. 2007, 130: 799-815. 10.1093/brain/awl382.CrossRefPubMed
56.
go back to reference Gaugler MN, Genc O, Bobela W, Mohanna S, Ardah MT, El-Agnaf OM, Cantoni M, Bensadoun JC, Schneggenburger R, Knott GW, et al: Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol. 2012, 123: 653-669. 10.1007/s00401-012-0963-y.CrossRefPubMed Gaugler MN, Genc O, Bobela W, Mohanna S, Ardah MT, El-Agnaf OM, Cantoni M, Bensadoun JC, Schneggenburger R, Knott GW, et al: Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol. 2012, 123: 653-669. 10.1007/s00401-012-0963-y.CrossRefPubMed
57.
go back to reference Barkholt P, Sanchez-Guajardo V, Kirik D, Romero-Ramos M: Long-term polarization of microglia upon alpha-synuclein overexpression in nonhuman primates. Neuroscience. 2012, 208: 85-96.CrossRefPubMed Barkholt P, Sanchez-Guajardo V, Kirik D, Romero-Ramos M: Long-term polarization of microglia upon alpha-synuclein overexpression in nonhuman primates. Neuroscience. 2012, 208: 85-96.CrossRefPubMed
Metadata
Title
rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration
Authors
Marusela Oliveras-Salvá
Anke Van der Perren
Nicolas Casadei
Stijn Stroobants
Silke Nuber
Rudi D’Hooge
Chris Van den Haute
Veerle Baekelandt
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Neurodegeneration / Issue 1/2013
Electronic ISSN: 1750-1326
DOI
https://doi.org/10.1186/1750-1326-8-44

Other articles of this Issue 1/2013

Molecular Neurodegeneration 1/2013 Go to the issue